Background: Irrespective of their clinical relevance, side effects cannot be considered a
negligible problem in antihypertensive therapy. The aim of this trial was to evaluate the …

Eleven centers in Tuscany, Italy, recruited 96 patients (aged 21-75 years) with mild-to-
moderate essential hypertension [diastolic blood pressure (DBP) 95-115 mm Hg; systolic …

BACKGROUND: It has been shown that administration of lacidipine markedly reduces
systolic blood pressure in elderly patients with hypertension without increasing the …

Outcome with Nifedipine GITS (ACTION) study in which nifedipine GITS was compared with
placebo, significant reductions of 28% and 27% were seen the incidence of any stroke or …

Lacidipine, a third generation dihydropyridine calciumantagonist, has demonstrated
pronounced anti-atherosclerotic activity in preclinical studies. The drug can act at several …

Calcium antagonists are effective in hypertensive patients of all ethnic groups, irrespective of
age, dietary salt intake, salt-sensitivity status or plasma renin activity profile. Some …

This review summarises the recent epidemiological data on hypertension, the aims of the
treatment of hypertension, and emphasizes the importance of the modification of target …

In the antihypertensive population, a normalisation of blood pressure level must be the first
objective. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)-Blood Pressure …

The clinical safety of the new dihydropyridine calcium antagonist lacidipine was assessed in
14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated with an …

Calcium antagonists, particularly the newer, longer-acting agents, are clearly effective in
reducing elevated blood pressure with minimal to modest adverse effect profiles, and are …